A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma
Leukemia & Lymphoma | January 11, 2018 | Volume: 59 | Issue: 9 | Pages: 2128-2134
10.1080/10428194.2017.1416368
| PMID 29320913